ENZYME REPLACEMENT THERAPY MARKET ANALYSIS
Competitive Landscape
Key players operating in the global enzyme replacement therapy market include Shire plc, Amicus Therapeutics, Genzyme Corporation, Pfizer Inc., BioMarin Pharmaceutical, Inc., Sigma-Tau Pharmaceuticals, Inc., Essential Pharmaceuticals Limited, Merck KGa, and AbbVie Inc.
Companies are undertaking significant amount of research for development of new enzyme replacement therapies, in turn being benefitted from orphan drug status and fast-track approval. Amicus Therapeutics was granted with orphan drug designation for its investigational combination drug therapy ATB200/AT2221 in November 2017. This drug is intended to cure Pompe disease (acid maltase deficiency or AMD).
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 
